An Orally Active Chemokine Receptor CCR2 Antagonist Prevents Glomerulosclerosis and Renal Failure in Type 2 Diabetes

Kidney International- United States

doi 10.1038/ki.2011.102

Full Text

Abstract

Available in

Categories

Date

July 1, 2011

Authors

Sufyan G. Sayyed

Onkar P. Kulkarni

Julia Lichtnekert

Patrizio Mattei

Hans-Joachim Anders

Publisher

Elsevier BV

Related search

Novel, Orally Bioavailable G-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

English

Functional Inhibition of Chemokine Receptor CCR2 by Dicer-Substrate-siRNA Prevents Pain Development

Molecular Medicine

Molecular Neuroscience

English

Cerebral Microvascular Disease Predicts Renal Failure in Type 2 Diabetes

Journal of the American Society of Nephrology : JASN

English

SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Arteriosclerosis, Thrombosis, and Vascular Biology

Cardiovascular Medicine

English

Alkylsulfone-Containing Trisubstituted Cyclohexanes as Potent and Bioavailable Chemokine Receptor 2 (CCR2) Antagonists

Bioorganic and Medicinal Chemistry Letters

Organic Chemistry

Molecular Medicine

Molecular Biology

Clinical Biochemistry

Pharmaceutical Science

English

Chemokine Receptor Genotype Is Associated With Diabetic Nephropathy in Japanese With Type 2 Diabetes

Internal Medicine

English

Factors Affecting Progression of Renal Failure in Patients With Type 2 Diabetes

Internal Medicine

Specialized Nursing

English

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Chemical and Pharmaceutical Bulletin

English

Impaired Neuropathic Pain Responses in Mice Lacking the Chemokine Receptor CCR2

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English